Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25879620 | 0.94 | — | — | |
| SCHEMBL18596097 | 0.86 | CHRNA7 (0.31) | — | |
| SCHEMBL12368455 | 0.76 | INMT (0.39) | — | |
| SCHEMBL25882157 | 0.74 | LMNA (0.35) | — | |
| SCHEMBL25879613 | 0.70 | INMT (0.30) | — | |
| SCHEMBL17344760 | 0.68 | TP53 (0.34) | — | |
| SCHEMBL19458925 | 0.67 | — | — | |
| SCHEMBL25879616 | 0.67 | INMT (0.32) | — | |
| SCHEMBL25879618 | 0.65 | PIK3CD (0.33) | — | |
| SCHEMBL105138 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227474-A1 | COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230227474-A1 | COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20150246888-A1 | ENOYL REDUCTASE INHIBITORS WITH ANTIBACTERIAL ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227474-A1 | COMPOSITIONS AND METHODS FOR CORRECTION OF ABERRANT SPLICING | RBM17, SF3B1, SF3B5 | JAK2 4540/4885 |
| US-20150246888-A1 | ENOYL REDUCTASE INHIBITORS WITH ANTIBACTERIAL ACTIVITY | TECR, FAR1, ECI1 | JAK2 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.